BiotechTube

Solriamfetol Oral Tablet + Placebo

ApprovedTerminated
0 watching 0 views this week🔥 Hot
82
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Excessive Sleepiness

Conditions

Excessive Sleepiness, Shift-work Disorder

Trial Timeline

Jul 21, 2021 → Apr 19, 2024

NCT ID
NCT04788953

About Solriamfetol Oral Tablet + Placebo

Solriamfetol Oral Tablet + Placebo is a approved stage product being developed by Axsome Therapeutics for Excessive Sleepiness. The current trial status is terminated. This product is registered under clinical trial identifier NCT04788953. Target conditions include Excessive Sleepiness, Shift-work Disorder.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT04788953ApprovedTerminated

Competing Products

8 competing products in Excessive Sleepiness

See all competitors
ProductCompanyStageHype Score
Placebo + PF-03654746PfizerPhase 2
51
JZP-110Jazz PharmaceuticalsPhase 2
49
Solriamfetol + PlaceboAxsome TherapeuticsApproved
82
Solriamfetol 150 MG + PlaceboAxsome TherapeuticsPhase 3
74
Solriamfetol 150 mg + Solriamfetol 300 mg + PlaceboAxsome TherapeuticsPhase 3
74
Fibrin Sealant Grifols + EVICELGrifolsPhase 3
74
ORX142 TabletsCentessa PharmaceuticalsPhase 1
28
VSF-173Vanda PharmaceuticalsPhase 2
44

Other Products from Axsome Therapeutics

Solriamfetol + PlaceboApproved
82
Solriamfetol 75 MGApproved
82
AXS-05 + BupropionApproved
82
AXS-05 (dextromethorphan and bupropion) oral tabletsPhase 3
74
AXS-07 (meloxicam-rizatriptan)Phase 3
74